#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Indolent systemic mastocytosis PIK3CA related overgrowth spectrum Behcet's syndrome Primary adrenal insufficiency Hydrocephalus Hidradenitis SAPHO syndrome Immune-mediated enterocolitis Nasopharyngeal cancer Dilated cardiomyopathy T-cell lymphoma Adenovirus infection Lupus nephritis Neoplasm malignant Vascular calcification More trials…

    Learn about Rare Diseases

    Erdheim-Chester disease Hairy cell leukaemia – Treatment Haemophilia – Basic Information Thrombotic thrombocytopenic purpura – Trials in Disease Indolent systemic mastocytosis – Diagnostics Cystic fibrosis lung – Diagnostics Congenital generalised lipodystrophy – Treatment Pleomorphic leiomyosarcoma – Basic Information Fabry’s disease – Basic Information Carcinoid syndrome – Trials in Disease More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Oxymetazoline Hydrochloride Enx-101 Teriparatide Carbetocin Vanglusagene Ensiparvovec Selgantolimod Navtemadlin Amy109 Ly3484356 ANTIMETABOLITES Serpina1(Human)-Aav8-1 Leriglitazone AMODIAQUINE Guselkumab Zanidatamab Doxylamine Hydrogen Succinate Deutivacaftor Agomelatine Mk-1167 Cenerimod More therapies…

    Learn about Your Condition

    Endocarditis enterococcal Retroperitoneal fibrosis Essential hypertension Tardive dyskinesia Peritoneal sarcoma Chordoma Pyrexia Dystonia Tooth loss Haematological infection Acute kidney injury Tendon disorder Insomnia Immune-mediated myositis Spinal pain More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

Gastroenteropancreatic neuroendocrine tumour disease

  • Study of Gallium (68Ga) edotreotide, Fluorocholine (18F) and Fludeoxyglucose (18F) PET imaging for detection and staging of liver cancer and gastro-entero-pancreatic tumors

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Hepatocellular carcinoma
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Fludeoxyglucose (18F)
    France

  • Study of Lutetium-177-DOTA-TATE with octreotide LAR in newly diagnosed patients with advanced gastroenteropancreatic neuroendocrine tumors (GEP-NET) with high disease burden

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Arginine Hydrochloride
    • Dimeticone
    • Lysine Hydrochloride
    France Germany Hungary Italy The Netherlands Poland +1

  • Comparing tarlatamab with standard chemotherapy in patients with pre-treated advanced pulmonary or gastroenteropancreatic neuroendocrine carcinomas

    Recruiting

    3 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour of the lung
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Dacarbazine
    • Tarlatamab
    • Topotecan
    France

  • Study of 64Cu-DOTATATE and 18F-FDG PET/CT imaging to predict disease progression in patients with neuroendocrine neoplasms

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    • Neuroendocrine tumour
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Copper (64Cu) Chloride
    • Fludeoxyglucose (18F)
    • Dotatate
    Denmark

  • Study of Combined Imaging with Hyperpolarized [1-13C]Pyruvate and Fludeoxyglucose (18F) for Cancer Detection in Patients with Breast Cancer, Neuroendocrine Tumors, Lymphomas, or Sarcomas

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine carcinoma metastatic
    • Neuroendocrine tumour
    • Pancreatic neuroendocrine tumour
    Investigated Drugs:
    • Pyruvic Acid
    • Fludeoxyglucose (18F)
    Denmark

  • Study on the Safety and Effectiveness of Cabozantinib and Lanreotide for Patients with Gastroenteropancreatic and Thoracic Neuroendocrine Tumors

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Gastroenteropancreatic neuroendocrine tumour disease
    Investigated Drugs:
    • Lanreotide
    • Cabozantinib
    Italy
1 2 3
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!